Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 6.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,705 shares of the biotechnology company’s stock after purchasing an additional 816 shares during the period. Schechter Investment Advisors LLC’s holdings in Exelixis were worth $456,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in EXEL. Los Angeles Capital Management LLC lifted its holdings in shares of Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after purchasing an additional 704,786 shares during the period. Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $14,979,000. Burney Co. purchased a new stake in Exelixis during the fourth quarter worth $12,267,000. Finally, Robeco Institutional Asset Management B.V. grew its holdings in Exelixis by 263.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company’s stock valued at $12,536,000 after purchasing an additional 350,026 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Piper Sandler lifted their price target on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Guggenheim reaffirmed a “buy” rating and issued a $42.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Truist Financial increased their price target on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Stifel Nicolaus lifted their price objective on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. Finally, BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and increased their target price for the company from $36.00 to $40.00 in a report on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.24.

Exelixis Price Performance

Shares of EXEL stock opened at $38.65 on Thursday. The firm has a market cap of $10.82 billion, a P/E ratio of 21.84, a PEG ratio of 1.13 and a beta of 0.57. The firm’s 50-day simple moving average is $34.81 and its 200-day simple moving average is $31.91. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $39.30.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the company’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. This represents a 2.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.